Clinical Trials
174 trialsDOXO75
Philogen S.p.A.
FIBROSARC
Philogen S.p.A.
Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors
Blokhin's Russian Cancer Research Center
BV-AVD-R Treatment Children Hodgkin's Lymphoma
Beijing Children's Hospital
FIBROSARC US
Philogen S.p.A.
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
Tracon Pharmaceuticals Inc.
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
Northwestern University
Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial
Zhujiang Hospital
FB-12
NSABP Foundation Inc
Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial
Zhujiang Hospital
Anrotinib Hydrochloride Combined With Adriamycin for Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma
Henan Cancer Hospital
Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma
Sun Yat-sen University
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
NSABP Foundation Inc
TONIC
The Netherlands Cancer Institute
ZR2-CHOP
The First Affiliated Hospital with Nanjing Medical University
Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer
Peking University People's Hospital
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
SBRT or TACE for Advanced HCC
University of Aarhus
A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer
Jilin University
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
PETHEMA Foundation
Brentuximab Vedotin in Combination With CHEP in Patient With PTCL
Czech Lymphoma Study Group
Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma
Shengjing Hospital
LYTPET
British Columbia Cancer Agency
Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer
Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
BeyondSpring Pharmaceuticals Inc.
Biomarker Guided Treatment in DLBCL
Ruijin Hospital
HD16
University of Cologne
The Effect of Metformin on Breast Cancer Patients
Beni-Suef University
Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma
Fudan University
PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients
Acrotech Biopharma Inc.
DR-CHOP
Ruijin Hospital
PDD vs PAD to Treat Initially Diagnosed MM
The First Affiliated Hospital of Soochow University
PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage
Hunan Cancer Hospital
(Optimist)
King Abdullah International Medical Research Center
MBC1
N.N. Petrov National Medical Research Center of Oncology
CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin
CBA Research
Effectiveness of Drug Eluting TACE in Primary HCC
Assiut University
GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL
Sun Yat-sen University
Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma
Peking University
Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)
Fudan University
Trial of DA-EPOCH Regimen for NHL With HLH
The First Affiliated Hospital with Nanjing Medical University
Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients
Peking University